Avinger Inc (AVGR) Stock

DelistedNasdaq: AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany.

0.47
Final close · Feb 14, 2025

AVGR is no longer traded. Avinger was delisted from the Nasdaq in February 2025.

Prices on this page are historical; the last trade was February 14, 2025 at $0.47.

Avinger stock price history

Split-adjusted closes, 2015–2025

AVGR final trading statistics

Final close
$0.47
Final trading day
Feb 14, 2025
Market cap at delisting
$1.52M
Shares outstanding
3.20M
Final 52-week range
$0.36 – $5.45
Avg. volume (final 3 mo.)
3,184,728
All-time high (split-adj.)
$1000000.00 · Jan 2015
All-time low (split-adj.)
$0.39 · Feb 2025
Return since IPO
-100.0%
Beta
1.09
Book value / share
$1.39
Price / book
0.34
Final 52 wk
0.365.45

Avinger earnings per share

Earnings per share

Avinger revenue & net income

RevenueNet income

Avinger annual financials

Avinger Inc revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2023$7.65M-$18.3M-$8.15
FY2022$8.27M-$17.4M-$4.74
FY2021$10.13M-$20.7M-$4.66
FY2020$8.76M-$19.8M-$16.00
FY2019$9.13M-$19.8M-$71.00

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Avinger Inc

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Avinger stock FAQ

What happened to Avinger stock?

Avinger stock was delisted from the Nasdaq. Its final close was $0.47 on February 14, 2025.

Is AVGR stock still trading?

No. AVGR was delisted from the Nasdaq in February 2025 and no longer trades on a U.S. exchange.

What was the last price of AVGR stock?

AVGR closed at $0.47 on its final trading day, February 14, 2025, for a market value of about $1.52M.

What were Avinger's revenue and earnings in its last full fiscal year?

Avinger reported revenue of $7.65M and net income of -$18.3M in fiscal 2023, its last full year as a public company.

When did Avinger go public?

Avinger Inc stock began trading on January 30, 2015.

Medical Instruments & Supplies stocks to research

All Healthcare stocks →